Research description

The general aim of my doctoral project is to optimise the use of current therapeutic strategies in patients with systemic lupus erythematosus. My project has two main branches: (i) to identify demographical, clinical and immunological factors that influence the efficacy of current therapies, with special focus on biologics targeting B cells; (ii) to determine the impact of pharmacological and non-pharmacological factors on patient’s health-related quality of life. Furthermore, we study the performance of different composite outcomes as well as patient reported outcomes in clinical trial settings.


Publication list

Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Gomez A, Jägerback S, Sjöwall C, Parodis I. Rheumatology (Oxford) 2023 May 25;kead253

Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Gomez A, Parodis I. Autoimmunity Reviews 2022;21(11):103188

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. Parodis I, Gomez A, Lindblom J, Weng J, Doria A, Gatto M. Frontiers in Medicine 2022;9:852162

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Emamikia S, Oon S, Gomez A, Lindblom J, Borg A, Enman E, Morand E, Grannas D, van Vollenhoven R, Nikpour M, Parodis I. Rheumatology (Oxford) 2022;61(12):4752-4762

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. Parodis I, Gomez A, Weng J, Borg A, Lindblom J, Gatto M. Frontiers Immunology 2022;13:796508

Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Frontiers in Medicine 2021; 8:651249

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Cobar F, Enman Y, Heintz E, Regardt M, Parodis I. Rheumatology (Oxford) 2021 Jan 27;keab080

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week long therapy in patients with systemic lupus erythematosus. Borg A, Gomez A, Cederlund A, Qiu V, Lindblom J, Emamikia S, Enman Y, Pettersson S, Parodis I. Rheumatology (Oxford) 2021 Jan 6; keaa909

Use of antimalarial agents is associated with favourable physical functioning in systemic lupus erythematosus. Gomez A, Soukka S, Johansson P, Åkerström E, Emamikia S, Enman Y, Chatzidionysiou K, Parodis I. J. Clin. Med. 2020; 9(6):1813

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Gomez A, Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I. Rheumatology (Oxford) 2021;60(3):1260-1272

Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Parodis I, Åkerström E, Sjöwall C, Sohrabian A, Jönsen A, Gomez A, Frodlund M, Zickert A, Bengtsson A, Rönnelid A, Gunnarsson I. Int. J. Mol. Sci. 2020, 21(10):3463 

Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin M, Weinmann-Menke J, Houssiau F, Tamirou F. Rheumatology (Oxford) 2020;59(11):3424-34

Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. Parodis I, Emamikia S, Gomez A, Gentline C, Arkema E, Chatzidionysiou K, van Vollenhoven RF. Lancet Rheumatology 2019;1(3):e163-73

Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Hernández-Breijo B, Gomez A, Soukka S, Johansson P, Parodis I. Autoimmunity Reviews 2019;18(10):102372

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Rheumatology (Oxford) 2019;58(12):2170-2176

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Parodis I, Gomez A, Emamikia S, Chatzidionysiou K. Annals of the rheumatic diseases 2019;78(7):1006-1007

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K. Expert Opin Biol Ther. 2018;19(2):157-68

Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Parodis I, Gomez A, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I. Expert Opin Biol Ther. 2018;18(8):911-20